#9775 Vimentin Antibody Sampler Kit
|Phospho-Vimentin (Ser56) Antibody #3877||20 µl||WB, IF-IC||H, M, Mk||57||Rabbit|
|Phospho-Vimentin (Ser83) Antibody #3878||20 µl||WB||H, M, R, Mk||57||Rabbit|
|Vimentin (D21H3) XP® Rabbit mAb #5741||20 µl||WB, IHC-P, IF-IC, F||H, M, R, Mk||57||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||WB||Goat|
Applications Key: W=Western Blotting, IF-IC=Immunofluorescence (Immunocytochemistry), IHC-P=Immunohistochemistry (Paraffin), F=Flow Cytometry
Reactivity Key: H=Human, M=Mouse, Mk=Monkey, R=Rat
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of extracts from various cell types, hydroxyurea-treated (4 mM) (G1/S) or paclitaxel-treated (100 nM) (G2/M) for 20 hours, using Phospho-Vimentin (Ser56) Antibody (upper). β-Actin Antibody #4967 was used as a loading control (lower).
Western blot analysis of extracts from HeLa cells, untreated or phosphorylated in vitro by PLK, using Phospho-Vimentin (Ser83) Antibody (upper). β-Actin Antibody #4976 (lower) was used as a loading control.
Western blot analysis of extracts from various cell lines using Vimentin (D21H3) XP® Rabbit mAb.
Confocal immunofluorescent analysis of SNB19 cells using Vimentin (D21H3) Rabbit mAb (green). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).
Confocal immunofluorescent analysis of HeLa cells using Phospho-Vimentin (Ser56) Antibody (green) and Phospho-Histone H3 (Ser10) (6G3) Mouse mAb #9706 (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using Vimentin (D21H3) XP® Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human tonsil using Vimentin (D21H3) XP® Rabbit mAb in the presence of control peptide (left) or antigen-specific peptide (right).
Immunohistochemical analysis of paraffin-embedded mouse colon using Vimentin (D21H3) XP® Rabbit mAb.
Flow cytometric analysis of HeLa cells, using Vimentin (D21H3) XP® Rabbit mAb (blue) compared to Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 (red).
The cytoskeleton consists of three types of cytosolic fibers: microfilaments (actin filaments), intermediate filaments, and microtubules. Major types of intermediate filaments are distinguished by their cell-specific expression: cytokeratins (epithelial cells), glial fibrillary acidic protein (GFAP) (glial cells), desmin (skeletal, visceral, and certain vascular smooth muscle cells), vimentin (mesenchyme origin), and neurofilaments (neurons). GFAP and vimentin form intermediate filaments in astroglial cells and modulate their motility and shape (1). In particular, vimentin filaments are present at early developmental stages, while GFAP filaments are characteristic of differentiated and mature brain astrocytes. Thus, GFAP is commonly used as a marker for intracranial and intraspinal tumors arising from astrocytes (2). Research studies have shown that vimentin is present in sarcomas, but not carcinomas, and its expression is examined in conjunction with that of other markers to distinguish between the two (3). Vimentin's dynamic structural changes and spatial re-organization in response to extracellular stimuli help to coordinate various signaling pathways (4). Phosphorylation of vimentin at Ser56 in smooth muscle cells regulates the structural arrangement of vimentin filaments in response to serotonin (5,6). Remodeling of vimentin and other intermediate filaments is important during lymphocyte adhesion and migration through the endothelium (7).
During mitosis, CDK1 phosphorylates vimentin at Ser56. This phosphorylation provides a PLK binding site for vimentin-PLK interaction. PLK further phosphorylates vimentin at Ser82, which might serve as memory phosphorylation site and play a regulatory role in vimentin filament disassembly (8,9). Additionally, studies using various soft-tissue sarcoma cells have shown that phosphorylation of vimentin at Ser39 by Akt1 enhances cell migration and survival, suggesting that vimentin could be a potential target for soft-tissue sarcoma targeted therapy (10,11).
- Eng, L.F. et al. (2000) Neurochem Res 25, 1439-51.
- Goebel, H.H. et al. (1987) Acta Histochem Suppl 34, 81-93.
- Leader, M. et al. (1987) Histopathology 11, 63-72.
- Helfand, B.T. et al. (2004) J Cell Sci 117, 133-41.
- Tang, D.D. et al. (2005) Biochem J 388, 773-83.
- Fomina, I.G. et al. (1990) Klin Med (Mosk) 68, 125-7.
- Nieminen, M. et al. (2006) Nat Cell Biol 8, 156-62.
- Yamaguchi, T. et al. (2005) J Cell Biol 171, 431-6.
- Oguri, T. et al. (2006) Genes Cells 11, 531-40.
- Zhu, Q.S. et al. (2011) Oncogene 30, 457-70.
- Xue, G. and Hemmings, B.A. (2013) J Natl Cancer Inst 105, 393-404.
DRAQ5 is a registered trademark of Biostatus Limited.
XP is a registered trademark of Cell Signaling Technology, Inc.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.